Your browser is no longer supported. Please, upgrade your browser.
NVAX Novavax, Inc. daily Stock Chart
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own0.20% Shs Outstand58.62M Perf Week-18.43%
Market Cap5.82B Forward P/E4.19 EPS next Y21.75 Insider Trans-74.17% Shs Float55.24M Perf Month-18.34%
Income-93.30M PEG- EPS next Q1.83 Inst Own53.40% Short Float14.16% Perf Quarter-34.69%
Sales50.20M P/S115.84 EPS this Y44.90% Inst Trans0.66% Short Ratio1.29 Perf Half Y347.30%
Book/sh3.15 P/B28.94 EPS next Y139.45% ROA-23.30% Target Price- Perf Year2000.46%
Cash/sh7.87 P/C11.58 EPS next 5Y0.00% ROE173.30% 52W Range3.54 - 189.40 Perf YTD2190.45%
Dividend- P/FCF181.72 EPS past 5Y5.60% ROI- 52W High-51.87% Beta1.51
Dividend %- Quick Ratio3.00 Sales past 5Y-9.50% Gross Margin- 52W Low2475.14% ATR8.23
Employees165 Current Ratio3.00 Sales Q/Q944.10% Oper. Margin- RSI (14)33.31 Volatility7.38% 7.28%
OptionableYes Debt/Eq1.74 EPS Q/Q82.30% Profit Margin- Rel Volume0.56 Prev Close98.36
ShortableYes LT Debt/Eq1.74 EarningsAug 10 AMC Payout- Avg Volume6.07M Price91.16
Recom2.70 SMA20-15.65% SMA50-19.58% SMA20049.03% Volume3,381,198 Change-7.32%
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Mar-29-18Upgrade Seaport Global Securities Neutral → Buy $5
Mar-19-18Downgrade JP Morgan Neutral → Underweight
Oct-20-20 10:12AM  
08:30AM  
Oct-18-20 06:18AM  
Oct-17-20 07:40AM  
06:09AM  
Oct-16-20 03:24PM  
01:53PM  
09:48AM  
06:26AM  
Oct-15-20 05:45PM  
04:31PM  
03:19PM  
11:31AM  
06:04AM  
Oct-14-20 10:36PM  
Oct-13-20 04:21PM  
04:18PM  
12:52PM  
11:20AM  
11:19AM  
10:31AM  
09:02AM  
08:00AM  
07:30AM  
06:05AM  
Oct-12-20 08:31AM  
07:08AM  
06:30AM  
Oct-10-20 06:14AM  
Oct-09-20 12:37PM  
12:30PM  
Oct-08-20 09:10PM  
05:45PM  
07:15AM  
06:15AM  
Oct-06-20 04:22PM  
03:37PM  
06:09AM  
Oct-05-20 09:00AM  
Oct-03-20 06:20AM  
Oct-02-20 04:55PM  
02:07PM  
12:12PM  
12:12PM  
10:23AM  
09:50AM  
09:38AM  
06:04AM  
Oct-01-20 06:08AM  
06:00AM  
06:00AM  
Sep-30-20 05:45PM  
02:54PM  
08:49AM  
Sep-29-20 10:25AM  
Sep-28-20 04:41PM  
09:31AM  
09:00AM  
06:30AM  
Sep-25-20 06:18PM  
04:12PM  
03:27PM  
02:16PM  
01:30PM  
12:55PM  
12:09PM  
12:09PM  
11:49AM  
10:39AM  
10:31AM  
09:59AM  
09:07AM  
08:23AM  
08:05AM  
07:37AM  
07:30AM  
07:00AM  
12:37AM  
Sep-24-20 10:23PM  
06:45PM  
04:35PM  
04:29PM  
04:13PM  
04:05PM  
12:14PM  
Sep-23-20 02:13PM  
01:28PM  
12:41PM  
07:03AM  
Sep-22-20 06:52PM  
05:19PM  
10:01AM  
Sep-21-20 05:45PM  
04:31PM  
Sep-20-20 08:23AM  
Sep-19-20 08:55AM  
Sep-18-20 04:44PM  
03:23PM  
03:12PM  
02:50PM  
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Erck Stanley CPresident and CEOOct 01Sale108.57221720,494Oct 01 05:39 PM
Trizzino JohnEVP, CBO and CFOSep 30Sale110.222,250248,0025,087Oct 01 05:40 PM
Erck Stanley CPresident and CEOSep 30Sale110.2312,2311,348,20020,496Oct 01 05:39 PM
Erck Stanley CPresident and CEOSep 29Sale107.804,112443,26732,727Sep 30 09:27 PM
Trizzino JohnEVP, CBO and CFOSep 29Sale107.2918,3211,965,6307,337Sep 30 09:28 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 29Sale107.3118,0291,934,667275Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 29Sale107.0219,9492,134,8441,561Sep 30 09:29 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Option Exercise5.9524,750147,26343,054Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 28Option Exercise5.9525,000148,75046,510Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 28Option Exercise5.9529,600176,12053,008Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 28Option Exercise5.9550,000297,50074,606Sep 30 09:27 PM
Erck Stanley CPresident and CEOSep 28Sale110.3025,0002,757,45636,839Sep 30 09:27 PM
Trizzino JohnEVP, CBO and CFOSep 28Sale110.3025,0002,757,45625,658Sep 30 09:28 PM
Glenn Gregory MPresident, R&DSep 28Sale110.3025,0002,757,45621,510Sep 30 09:29 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Sale110.3024,7502,729,87918,304Sep 30 09:30 PM
EVANS GARY CDirectorAug 18Option Exercise31.0210,500325,700332,479Aug 20 06:09 PM
Glenn Gregory MPresident, R&DAug 18Option Exercise33.5655,9211,876,52557,760Aug 20 06:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Option Exercise53.8246,2422,488,61346,517Aug 20 06:20 PM
MCMANUS MICHAEL A JRDirectorAug 18Option Exercise27.608,000220,80017,951Aug 20 06:22 PM
Trizzino JohnEVP, CBO and CFOAug 18Option Exercise50.9542,7882,179,98647,875Aug 20 06:25 PM
MCMANUS MICHAEL A JRDirectorAug 18Sale146.008,0001,168,0009,951Aug 20 06:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Sale144.3346,2426,673,982275Aug 20 06:20 PM
Glenn Gregory MPresident, R&DAug 18Sale145.2055,9218,119,8601,839Aug 20 06:14 PM
EVANS GARY CDirectorAug 18Sale150.4410,5001,579,620321,979Aug 20 06:09 PM
Trizzino JohnEVP, CBO and CFOAug 18Sale148.7842,7886,366,1825,087Aug 20 06:25 PM
Glenn Gregory MPresident, R&DJun 18Option Exercise42.2016,749706,80818,588Jun 22 05:29 PM
Glenn Gregory MPresident, R&DJun 18Sale59.5316,749997,1031,839Jun 22 05:29 PM
YOUNG JAMES FDirectorJun 03Buy48.831,50073,2451,500Jun 05 05:04 PM
Herrmann John A IIISVP, General CounselMay 18Option Exercise26.1912,961339,4487,774May 20 04:35 PM
Herrmann John A IIISVP, General CounselMay 18Sale49.4412,961640,792275May 20 04:35 PM
Glenn Gregory MPresident, R&DJan 31Buy3.861,2504,8251,373Feb 04 05:11 PM
MCMANUS MICHAEL A JRDirectorNov 18Sale3.823,92915,0159,951Nov 20 04:17 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.